January 28, 2009 — On January 16, the US Food and Drug Administration (FDA) granted accelerated approval to human fibrinogen concentrate (RiaSTAP, CSL Behring). This orphan drug is intended for use in ...
Before soluble fibrinogen, a blood plasma protein, is converted into insoluble fibrin molecules that can toxically accumulate outside blood vessels in the brain, fibrinogen connects directly with ...
Fibrin formation is pivotal in hemostasis, serving as a temporary barrier to blood loss following vascular injury, while in thrombosis this process is involved in thrombus progression, stability, and ...
A new study from the University of Alberta demonstrated that the blood clotting protein called fibrinogen also regulates MMP-2, an enzyme involved in immunity and in clot formation inside blood ...
Activation of the immune system has been increasingly recognised to be associated with procoagulatory status in patients with inflammatory rheumatic disease. Changes in endothelial cell and platelet ...
Expanded indication makes Fibryga the first and only on-demand, virus-inactivated, human plasma-derived fibrinogen concentrate approved for this indication. The FDA has approved an expanded indication ...
New research reveals that fibrin, a key component of blood clots, may be the secret culprit behind the devastating neurological and inflammatory aftermath of the virus, including long COVID. From ...
Long COVID has become a significant public health concern, with coagulation and neurological complications arising during acute infection and persisting into the post-acute phase, contributing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results